FDA
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
Amylyx discontinues AMX0035 trial for progressive supranuclear palsy
-
-
-
-
-
-
-
Amylyx Pharmaceuticals (AMLX) Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX)
-
328,333 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

